# Hypertension (Essential Hypertension)

## Overview
Essential hypertension is persistently elevated blood pressure without an identifiable underlying medical cause. It accounts for 90-95% of all hypertension cases.

## Key Information
- **ICD-10 Code**: I10 (Essential hypertension)
- **Prevalence**: ~45% of US adults
- **Age of Onset**: Typically develops gradually over years
- **Risk Factors**: Age, family history, obesity, high sodium intake, physical inactivity, excessive alcohol

## Pathophysiology
- Increased peripheral vascular resistance
- Enhanced sympathetic nervous system activity
- Abnormal renal sodium handling
- Endothelial dysfunction
- Arterial stiffening with age

## Clinical Presentation

### Symptoms
- Often asymptomatic ("silent killer")
- Headaches (typically occipital, morning)
- Dizziness or lightheadedness
- Nosebleeds (rare, severe cases)
- Shortness of breath with exertion
- Chest pain (if cardiac involvement)

### Physical Findings
- Elevated blood pressure readings
- Retinal changes (AV nicking, cotton wool spots, papilledema)
- Left ventricular hypertrophy (PMI displacement)
- S4 gallop
- Carotid bruits

## Diagnostic Criteria and Evaluation

### Blood Pressure Classification (2017 AHA/ACC Guidelines)
```mermaid
graph TD
    A[Blood Pressure Reading] --> B{Systolic/Diastolic}
    B -->|<120 and <80| C[Normal]
    B -->|120-129 and <80| D[Elevated]
    B -->|130-139 or 80-89| E[Stage 1 HTN]
    B -->|≥140 or ≥90| F[Stage 2 HTN]
    B -->|>180 or >120| G[Hypertensive Crisis]
    
    E --> H[Confirm with Home Monitoring]
    F --> I[Confirm with Home Monitoring]
    G --> J[Immediate Evaluation]
```

### Initial Workup
- **Confirm Diagnosis**: Multiple readings, home BP monitoring, 24-hour ambulatory monitoring
- **Laboratory Tests**:
  - Basic metabolic panel (electrolytes, creatinine, eGFR)
  - Fasting glucose and HbA1c
  - Lipid profile
  - TSH
  - Urinalysis and urine microalbumin
- **Imaging**: ECG, echocardiogram if LVH suspected
- **Assess for Secondary Causes** (if indicated)

## Treatment Algorithm

```mermaid
graph TD
    A[Confirmed Hypertension] --> B{Stage 1 HTN<br/>130-139/80-89}
    A --> C{Stage 2 HTN<br/>≥140/90}
    
    B --> D{ASCVD Risk ≥10%<br/>or High Risk?}
    D -->|Yes| E[Lifestyle + Medication]
    D -->|No| F[Lifestyle Modifications<br/>3-6 months]
    F --> G{BP Goal Achieved?}
    G -->|No| E
    G -->|Yes| H[Continue Lifestyle]
    
    C --> I[Lifestyle + Medication]
    
    E --> J[Start ACE-I/ARB or<br/>Thiazide Diuretic]
    I --> K[Start 2 medications<br/>Different classes]
    
    J --> L{Goal <130/80?}
    K --> L
    L -->|No| M[Add/Adjust Medications]
    L -->|Yes| N[Continue Current Therapy]
    
    M --> O[Consider Combination:<br/>ACE-I/ARB + Thiazide + CCB]
```

## Management

### Lifestyle Modifications (First-line for all patients)
- **Weight Loss**: 5-20 mmHg reduction per 10kg weight loss
- **DASH Diet**: 8-14 mmHg reduction
  - High fruits, vegetables, low-fat dairy
  - Reduced saturated fat and total fat
- **Sodium Restriction**: <2.3g daily (ideal <1.5g) - 2-8 mmHg reduction
- **Physical Activity**: 150 min/week moderate exercise - 4-9 mmHg reduction
- **Alcohol Limitation**: ≤2 drinks/day men, ≤1 drink/day women - 2-4 mmHg reduction
- **Smoking Cessation**: Improves cardiovascular risk

### Pharmacological Treatment

#### First-Line Agents
1. **ACE Inhibitors**
   - Lisinopril: 10-40mg daily
   - Enalapril: 5-20mg twice daily
   - Side effects: Dry cough (10%), hyperkalemia, angioedema

2. **Angiotensin Receptor Blockers (ARBs)**
   - Losartan: 50-100mg daily
   - Valsartan: 80-320mg daily
   - Preferred if ACE-I intolerant

3. **Thiazide/Thiazide-like Diuretics**
   - Hydrochlorothiazide: 25-50mg daily
   - Chlorthalidone: 12.5-25mg daily (preferred)
   - Monitor: Electrolytes, kidney function

4. **Calcium Channel Blockers**
   - Amlodipine: 5-10mg daily
   - Nifedipine XL: 30-90mg daily
   - Side effects: Peripheral edema, gingival hyperplasia

#### Second-Line Agents
- **Beta-blockers**: Metoprolol, Carvedilol (if heart failure, post-MI)
- **Aldosterone Antagonists**: Spironolactone (if resistant HTN)

### Target Blood Pressures
- **General Population**: <130/80 mmHg
- **Diabetes**: <130/80 mmHg
- **CKD**: <130/80 mmHg
- **Elderly (>65)**: <130/80 mmHg if tolerated

## Complications

### Acute Complications
- **Hypertensive Emergency**: BP >180/120 with end-organ damage
- **Hypertensive Urgency**: BP >180/120 without end-organ damage

### Chronic Complications
- **Cardiovascular**: Coronary artery disease, heart failure, arrhythmias
- **Cerebrovascular**: Stroke, transient ischemic attacks
- **Renal**: Chronic kidney disease, end-stage renal disease
- **Retinal**: Hypertensive retinopathy, vision loss
- **Peripheral Vascular**: Peripheral artery disease

## Special Populations

### Pregnancy
- **Chronic HTN**: Continue safe medications (methyldopa, labetalol, nifedipine)
- **Gestational HTN**: Monitor closely, deliver if severe
- **Preeclampsia**: Immediate obstetric consultation

### Diabetes
- Preferred agents: ACE-I or ARB (renoprotective)
- Target: <130/80 mmHg
- Monitor kidney function closely

### Heart Failure
- Preferred agents: ACE-I/ARB + beta-blocker + diuretic
- Avoid: Non-dihydropyridine CCBs

## Monitoring

### Follow-up Schedule
- **Initiation**: 2-4 weeks after starting/changing medication
- **Stable**: Every 3-6 months
- **Uncontrolled**: Monthly until goal achieved

### Home Blood Pressure Monitoring
- Validated device with appropriate cuff size
- Take readings same time daily
- Average multiple readings over 1 week
- Target: <130/80 mmHg

### Laboratory Monitoring
- **Baseline**: Complete metabolic panel
- **Follow-up**: Electrolytes and creatinine 2-4 weeks after ACE-I/ARB/diuretic initiation
- **Ongoing**: Annual labs if stable

## Related Conditions
- [Type 2 Diabetes](diabetes-type-2.md) - Often coexistent
- [Coronary Artery Disease](coronary-artery-disease.md)
- [Heart Failure](heart-failure.md)
- [Chronic Kidney Disease](chronic-kidney-disease.md)
- [Metabolic Syndrome](metabolic-syndrome.md)

## Key References
- [2017 AHA/ACC Hypertension Guidelines](https://www.ahajournals.org/doi/10.1161/HYP.0000000000000065)
- [SPRINT Trial Results](https://www.nejm.org/doi/full/10.1056/NEJMoa1511939)
- [JNC 8 Guidelines](https://jamanetwork.com/journals/jama/fullarticle/1791497)
- [DASH Diet Information](https://www.nhlbi.nih.gov/education/dash-eating-plan)

## Recent Updates
- **2024**: Updated cardiovascular risk calculators
- **2023**: New data on SGLT2 inhibitors in hypertension
- **2022**: Revised guidelines for elderly patients
